Filings/CTMX/IR

CYTOMX THERAPEUTICS, INC. IR

financial tables · 2019

CX-072, a PD-L1 Probody Therapeutic, as Monotherapy in Patients With Advanced Solid Tumors: Preliminary Results of PROCLAIM-CX-072

Source document

Issuer site
Loading document…
CX-072, a PD-L1 Probody Therapeutic, as Monotherapy in Patients With Advanced Solid Tumors: Preliminary Results of PROCLAIM-CX-072 — CYTOMX THERAPEUTICS, INC.